Novo Nordisk (NVO) and Eli Lilly (LLY) stocks are in focus as the duo plan to launch direct sales of weight loss drugs to ...

LLY???s newest approvals and pipeline deals add fresh momentum to revenue growth as the company expands beyond its GLP-1 ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid ...

But these eye-popping innovations have an effect only if they can make their way to the patients who need them. That reality ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

Bayer opened a new biotech incubator in Beijing. A first-of-its-kind biosimilar originally developed by Shanghai Henlius ...

Findings show that inclusive attitudes among Italian oncologists coexist with clear knowledge and awareness gaps highlighting ...

The direct-to-consumer model is now being applied to the patient experience and broader healthcare system. New tools are reducing barriers and friction, offering greater choice and personalization and ...

FDA decision-making may be reduced to a sequence of ‘make-a-deals’ with Trump, his FDA, or even political allies,” experts ...

Trial participants who used eloralintide, a new weight loss medication that, instead of focusing on the hormone GLP-1, ...

Philadelphia is the newest destination for Lilly Gateway Labs, an incubator for early-stage biotech companies backed by pharmaceutical giant Eli Lilly & Co., the company announced Wednesday. The ...